{"slideshow_credits": null, "snippet": "The three drugs &#8212; Eylea, Lucentis and Avastin &#8212; are meant to treat a condition known as macular edema, which occurs primarily in patients with diabetes.", "abstract": "Study published in New England Journal of Medicine finds that drugs Eylea, Lucentis and Avastin are equally effective as treatments for form of vision loss caused by diabetes, although prices for drugs range from $50 to $1,950 per dose; study comes at time of concern over costs of pharmaceuticals.", "section_name": "Business Day", "print_page": "7", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK"}, "web_url": "http://www.nytimes.com/2015/02/19/business/3-drugs-for-an-eye-disease-with-big-price-gaps-are-found-to-be-equals.html", "lead_paragraph": "The three drugs &#8212; Eylea, Lucentis and Avastin &#8212; are meant to treat a condition known as macular edema, which occurs primarily in patients with diabetes.", "headline": {"main": "3 Drugs for an Eye Disease, With Big Price Gaps, Are Found to Be Equals for Many", "print_headline": "A Study Sizes Up 3 Eye Drugs With Big Price Gaps"}, "_id": "54e51c6038f0d82d01cf7598", "word_count": "807", "multimedia": [{"height": 126, "url": "images/2015/02/19/business/19EYE/19EYE-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/02/19/business/19EYE/19EYE-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 600, "url": "images/2015/02/19/business/19EYE/19EYE-articleLarge.jpg", "legacy": {"xlarge": "images/2015/02/19/business/19EYE/19EYE-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "600"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/02/19/business/19EYE/19EYE-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/02/19/business/19EYE/19EYE-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-02-19T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "subject", "value": "Eyes and Eyesight", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "New England Journal of Medicine", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Research", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Eylea (Drug)", "is_major": "N", "rank": "5"}, {"name": "organizations", "value": "National Eye Institute", "is_major": "N", "rank": "6"}, {"name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "7"}], "blog": [], "subsection_name": null, "type_of_material": "News"}